Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer. | Endocrine | 2026 | 42804115 | PubTator, text mining | PubMed |
| Retraction: Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage. | PLoS One | 2026 | 42784551 | PubTator, text mining | PubMed |
Retraction: Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. | PLoS One | 2026 | 42691019 | PubTator, text mining | PubMed |
| Association between Alzheimer's disease-related genes and neurodegenerative blood-based biomarkers in Indian adults. | Front Aging Neurosci | 2026 | 42688218 | PubTator, text mining | PubMed |
| Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. | Science | 2026 | 42658930 | PubTator, text mining | PubMed |
| Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. | Thorac Cancer | 2026 | 42503459 | PubTator, text mining | PubMed |
| Nonsense-mediated mRNA decay as a gatekeeper of neoantigen expression: Bridging RNA surveillance and tumor immunotherapy. | Mol Biol Rep | 2026 | 42461475 | PubTator, text mining | PubMed |
| The regulation of protein phosphatase 4 by FBXO42 is required for cancer cell survival. | EMBO Rep | 2026 | 42448956 | PubTator, text mining | PubMed |
| Holding the PP2A and PP4 protein phosphatases at bay: emerging roles of FBXO42 and CCDC6. | EMBO Rep | 2026 | 42448955 | PubTator, text mining | PubMed |
| KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. | Apoptosis | 2026 | 42448954 | PubTator, text mining | PubMed |
| Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review. | Front Oncol | 2026 | 42444822 | PubTator, text mining | PubMed |
| Author Correction: PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components. | Nature | 2026 | 42265482 | PubTator, text mining | PubMed |
| Nonsense-mediated mRNA decay: friend or foe in cancer biology? | Cell Commun Signal | 2026 | 42260649 | PubTator, text mining | PubMed |
| Targeted therapy combined with local consolidative surgery for oligometastatic stage IVA lung adenocarcinoma with CCDC6-RET fusion: a case report. | Front Oncol | 2026 | 42245729 | PubTator, text mining | PubMed |
| CCDC6, a ferroptosis-related gene, modulates stemness features of pancreatic cancer cells in vitro. | BMC Cancer | 2026 | 42219468 | PubTator, text mining | PubMed |
| Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report. | Lung Cancer (Auckl) | 2026 | 42199509 | PubTator, text mining | PubMed |
| Molecular Characterisations and the Association with Clinical Factors in RET Fusion-Positive NSCLC: A Retrospective Study of the Single Center Cohort. | Cancer Manag Res | 2026 | 42088459 | PubTator, text mining | PubMed |
| Molecular Landscape in Pediatric and Young Adult Thyroid Cancer: A Brazilian Cohort Study. | Cancer Genet | 2026 | 42085892 | PubTator, text mining | PubMed |
| A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations. | Clin Lung Cancer | 2026 | 42055889 | PubTator, text mining | PubMed |
| Case Report: Unclassifiable cerebellar high-grade neuroepithelial tumor with a CCDC6::RET fusion manifesting explosive recurrence. | Front Surg | 2026 | 42027864 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers